Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 205

Sort by

Sort Order Select

Journal Articles

Efficacy of motixafortide plus G-CSF versus plerixafor plus G-CSF for stem cell mobilization and collection in multiple myeloma: A single-center comparative analysis and interim Results from a prospective study in poor mobilizers

Sara Close, Jun Liu, Lara Abousamra, Suhayla Sarhan, Kristine Geary, Sanjana Arji, Claire Shao, Eileen Green, Yuxin Liu, Paul Richardson, John Manis, Corey Cutler, Sarah Nikiforow, Clifton Mo

Blood (2025) 146 (Supplement 1): 4185.

https://doi.org/10.1182/blood-2025-4185

Published: 2025

Journal Articles

Risk factors and prevalence of monoclonal gammopathy of undetermined significance (MGUS) by duffy genotype

Lauren Merz, Sabine Allam, Sungjae Kim, Jean-Baptiste Alberge, Jacqueline Perry, David Lee, Katherine Padgett, Julia Colchie, Omar Nadeem, Irene Ghobrial, Paul Richardson

Blood (2025) 146 (Supplement 1): 4578.

https://doi.org/10.1182/blood-2025-4578

Published: 2025

Journal Articles

Results of the Phase II d-PRISM study: Daratumumab in high-risk MGUS and low-risk smoldering myeloma

Blood (2025) 146 (Supplement 1): 1533.

https://doi.org/10.1182/blood-2025-1533

Published: 2025

Journal Articles

An exploratory analysis of health-related quality of life measures with belantamab mafodotin in combination with pomalidomide and dexamethasone (BPd) in patients with relapsed or refractory multiple myeloma (RRMM) enrolled in dreamm-8

Paul Richardson, Craig Cole, Angely Loubert, Laurine Bunod, Manal M'Hari, Pralay Mukhopadhyay, Sandhya Sapra, Molly Purser, Benga Kazeem, Farrah Pompilus, Sagar Lonial

Blood (2025) 146 (Supplement 1): 2284.

https://doi.org/10.1182/blood-2025-2284

Published: 2025

Journal Articles

Quality initiative in first-line multiple myeloma assessing the use of anti-CD38 agents and quadruplet therapy

Joseph Franz, Dhaval Mehta, Kathleen Dorritie, Rushir Choksi, Taya Salman, Mike Gart, Lisa Kunst, Harshal Dave, Kristen Henn, Prashanth Jain, Brandon Wang, Prateesh Varughese, Lisa Morere, Jeffrey Scott, Paul Richardson

Blood (2025) 146 (Supplement 1): 8120.

https://doi.org/10.1182/blood-2025-8120

Published: 2025

Journal Articles

The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, Bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial

Blood (2025) 146 (Supplement 1): 1033.

https://doi.org/10.1182/blood-2025-1033

Published: 2025

Journal Articles

Factors impacting treatment choice with a CD38 antibody, immunomodulator, proteasome inhibitor, and dexamethasone in first line multiple myeloma patients: A real-world US study

Joseph Franz, Joseph Mikhael, Dhaval Mehta, Rushir Choksi, Taya Salman, Mike Gart, John Li, Harshal Dave, Lisa Kunst, Kristen Henn, Prashanth Jain, Brandon Wang, Prateesh Varughese, Lisa Morere, Jeffrey Scott, Paul Richardson

Blood (2025) 146 (Supplement 1): 3988.

https://doi.org/10.1182/blood-2025-3988

Published: 2025

Journal Articles

Pharmacodynamic activity and clinical benefits of mezigdomide in high-risk biomarker subgroups from the CC-92480-MM-001 study

Tracy Chow, Nicholas Stong, Keyur Desai, Saleh Tamim, Chad Bjorklund, Joseph Hadala, Cynthia Donahue, Phillip Koo, Erica Petrlik, Jessica Katz, Anita Gandhi, Suzanne Trudel, Nizar Bahlis, Paul Richardson, Michael Amatangelo

Blood (2025) 146 (Supplement 1): 5697.

https://doi.org/10.1182/blood-2025-5697

Published: 2025

Journal Articles

Maintenance therapy following chimeric antigen receptor T-cell therapy in relapsed and refractory multiple myeloma: An exploratory case series evaluating feasibility and safety in a real-world setting

Zohaib Ahmed, Walid Hamouche, Shonali Midha, Yuxin Liu, Adam Sperling, Clifton Mo, Jacob Laubach, Paul Richardson, Nikhil Munshi, Omar Nadeem

Blood (2025) 146 (Supplement 1): 7525.

https://doi.org/10.1182/blood-2025-7525

Published: 2025

Journal Articles

Belantamab mafodotin (belamaf) ocular events are manageable and reversible with dose modifications guided by standard assessments

Sagar Lonial, Paul Richardson, Craig Cole, Asim Farooq, Meghan Berkenstock, Julie Byrne, Sumita Roy-Ghanta, Rachel Rogers, Amy Phillips-Jones, Astrid McKeown, Natalie Afshari

Blood (2025) 146 (Supplement 1): 4055.

https://doi.org/10.1182/blood-2025-4055

Published: 2025

Journal Articles

A randomized phase II study of daratumumab, lenalidomide, ixazomib, and dexamethasone in transplant-ineligible or deferred patients with newly diagnosed multiple myeloma: Alliance Foundation Trial 41 (AFT-41)

Andrew Yee, Elizabeth O'Donnell, Omar Nadeem, Garth Nelson, Tanya Wildes, Tondre Buck, Sascha Tuchman, Krishna Ghimire, Sarah Sinclair, Catherine Stewart, Paul Richardson, Saad Usmani, Noopur Raje

Blood (2025) 146 (Supplement 1): 4053.

https://doi.org/10.1182/blood-2025-4053

Published: 2025

Journal Articles

Isatuximab (Isa) plus lenalidomide (R), Bortezomib (V), and dexamethasone (d) (Isa-RVd) as induction therapy in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Primary analysis of parallel phase 2 studies by the Dana-Farber Cancer Institute (DFCI) and Cancer Trials Ireland (CTI)

Blood (2025) 146 (Supplement 1): 4030.

https://doi.org/10.1182/blood-2025-4030

Published: 2025

Journal Articles

Health-related quality of life with belantamab mafodotin in patients with relapsed or refractory multiple myeloma (RRMM): An exploratory analysis of overall quality of life in dreamm-7

Sagar Lonial, Craig Cole, Angely Loubert, Laurine Bunod, Manal M'Hari, Pralay Mukhopadhyay, Sandhya Sapra, Molly Purser, Jacqueline Nielsen, Benga Kazeem, Farrah Pompilus, Paul Richardson

Blood (2025) 146 (Supplement 1): 4029.

https://doi.org/10.1182/blood-2025-4029

Published: 2025

Journal Articles

An open-label rollover study to assess the long-term safety of ixazomib

Sebastian Grosicki, Markus Hansson, Meletios Dimopoulos, Tadao Ishida, Vishal Kukreti, Dok Hyun Yoon, Wee-Joo Chng, Oliver Bechter, Xuejun Peng, Paul Richardson

Blood (2025) 146 (Supplement 1): 7547.

https://doi.org/10.1182/blood-2025-7547

Published: 2025

Journal Articles

Selinexor, mezigdomide, and dexamethasone in patients with Relapsed/Refractory multiple myeloma who relapsed or are ineligible for T-cell–redirecting therapy: Stomp Phase 1 results

Clifton Mo, Cristina Gasparetto, Cristiana Costa, Andrew Cowan, Tomer Mark, Yi Chai, Trinayan Kashyap, Jessica Katz, Michael Amatangelo, Paul Richardson

Blood (2025) 146 (Supplement 1): 4010.

https://doi.org/10.1182/blood-2025-4010

Published: 2025

Journal Articles

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

Blood (2020) 136 (22): 2513–2523.

https://doi.org/10.1182/blood.2020007522

Published: 2020

Includes: Supplemental data

Journal Articles

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

Joseph Mikhael, Paul Richardson, Saad Z. Usmani, Noopur Raje, William Bensinger, Chatchada Karanes, Frank Campana, Dheepak Kanagavel, Franck Dubin, Qianying Liu, Dorothée Semiond, Kenneth Anderson

Blood (2019) 134 (2): 123–133.

https://doi.org/10.1182/blood-2019-02-895193

Published: 2019

Journal Articles

CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias

Blood (2018) 132 (Supplement 1): 1367.

https://doi.org/10.1182/blood-2018-99-116232

Published: 2018

Journal Articles

OP-106 Horizon — Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS

Blood (2018) 132 (Supplement 1): 600.

https://doi.org/10.1182/blood-2018-99-113095

Published: 2018

Journal Articles

The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome

Blood (2018) 132 (Supplement 1): 749.

https://doi.org/10.1182/blood-2018-99-113059

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Efficacy of motixafortide plus G-CSF versus plerixafor plus G-CSF for stem cell mobilization and collection in multiple myeloma: A single-center comparative analysis and interim Results from a prospective study in poor mobilizers

Risk factors and prevalence of monoclonal gammopathy of undetermined significance (MGUS) by duffy genotype

Results of the Phase II d-PRISM study: Daratumumab in high-risk MGUS and low-risk smoldering myeloma

An exploratory analysis of health-related quality of life measures with belantamab mafodotin in combination with pomalidomide and dexamethasone (BPd) in patients with relapsed or refractory multiple myeloma (RRMM) enrolled in dreamm-8

Quality initiative in first-line multiple myeloma assessing the use of anti-CD38 agents and quadruplet therapy

Factors impacting treatment choice with a CD38 antibody, immunomodulator, proteasome inhibitor, and dexamethasone in first line multiple myeloma patients: A real-world US study

Pharmacodynamic activity and clinical benefits of mezigdomide in high-risk biomarker subgroups from the CC-92480-MM-001 study

Maintenance therapy following chimeric antigen receptor T-cell therapy in relapsed and refractory multiple myeloma: An exploratory case series evaluating feasibility and safety in a real-world setting

Belantamab mafodotin (belamaf) ocular events are manageable and reversible with dose modifications guided by standard assessments

A randomized phase II study of daratumumab, lenalidomide, ixazomib, and dexamethasone in transplant-ineligible or deferred patients with newly diagnosed multiple myeloma: Alliance Foundation Trial 41 (AFT-41)

Health-related quality of life with belantamab mafodotin in patients with relapsed or refractory multiple myeloma (RRMM): An exploratory analysis of overall quality of life in dreamm-7

An open-label rollover study to assess the long-term safety of ixazomib

Selinexor, mezigdomide, and dexamethasone in patients with Relapsed/Refractory multiple myeloma who relapsed or are ineligible for T-cell–redirecting therapy: Stomp Phase 1 results

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias

OP-106 Horizon — Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS

The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only